News
Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker
"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders," the statement said.
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...
Queen Latifah opens up about obesity and heart health risks for public awareness campaign, Truth About Weight.
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Deaths attributed to both acute heart attack and obesity rose between 2007 and 2019, according to findings from the CDC ...
A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...
If child with a high BMI reaches a healthy weight by the age of six, they are no longer at risk of becoming obese later in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback